Company intelligence / Profile preview
Micar Innovation
Sofia, Bulgariamicar21.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Micar Innovation has developed a portfolio of at least ten new small molecule drug candidates at various stages of preclinical development. Lead programs are advancing toward preclinical trials with demonstrated non-clinical proof-of-concept in areas such as chronic pain, pancreatic cancer, melasma. The company also launched an initiative to study over one hundred new molecules targeting rare/ultra‐rare diseases.
- Therapeutic areas
- PulmonologyCardiovascularDermatologyOncologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Major biopharmaceutical companies via Build-to-Buy partnershipsPioneering academic researchers/universities in EU & USA provide research collaboration/funding paths.
Beyond the preview
Go deeper on Micar Innovation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Micar Innovation.